Evidence map›Paper›PMID 39128337›Full record

ArticleGynecologic oncology2024

Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.

Xin Ray Tee, Emma Hazard, Elena Latorre-Esteves, Brendan F Kohrn, Talayeh S Ghezelayagh, Jeanne Uy Fredrickson, CoohleenAnn Coombes, Marc R Radke, Enna Manhardt, Ronit Katz and 4 more

Abstract read
In one paragraph

Article in Gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xin Ray TeeDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
Emma HazardDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
Elena Latorre-EstevesDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
Brendan F KohrnDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
Talayeh S GhezelayaghDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA; Department of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Jeanne Uy FredricksonDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
CoohleenAnn CoombesDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
Marc R RadkeDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Enna ManhardtDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Ronit KatzDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
T Rinda SoongDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Elizabeth M SwisherDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Barbara M NorquistDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Rosa Ana RisquesDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA. Electronic address: rrisques@uw.edu.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2M
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancerR01CA259384 · NCI · UNIVERSITY OF WASHINGTON · PI RISQUES, ROSA ANA · 2021 to 2025
$2.8M
Evaluation of TP53 mutations in non-cancerous tissue as novel biomarkers of ovarian cancer risk.R21CA240885 · NCI · UNIVERSITY OF WASHINGTON · PI RISQUES, ROSA ANA · 2019 to 2020
$372k
NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA259384NCI NIH HHS R21 CA240885NCI NIH HHS T32 CA009515
6 · The paper itself

Abstract

backgroundIndividuals with germline BRCA1 and BRCA2 pathogenic variants (BRCA carriers) are at high risk of developing high grade serous ovarian carcinoma (HGSC). HGSC is predominantly driven by TP53 mutations, but mutations in this gene are also commonly found in non-cancerous tissue as a feature of normal human aging. We hypothesized that HGSC predisposition in BRCA carriers may be related to increased TP53 somatic evolution, which could be detectable by ultra-deep sequencing of TP53 mutations in gynecological liquid biopsies.

methodsDuplex sequencing was used to identify TP53 mutations with high sensitivity in peritoneal washes and cervical liquid-based cytology (LBC) collected at surgery from 60 individuals including BRCA1 and BRCA2 carriers, and non-carriers. TP53 mutation pathogenicity was compared across groups and with TP53 cancer mutations.

resultsTP53 mutations were more abundant in cervical LBC than in peritoneal washes but increased with age in both sample types. In peritoneal washes, but not in cervical LBC, pathogenic TP53 mutation burden was increased in BRCA1 carriers compared to non-carriers, independently of age. Five individuals shared identical pathogenic TP53 mutations in peritoneal washes and cervical LBC, but not in blood.

conclusionsUltra-deep sequencing of TP53 mutations in peritoneal washes collected at surgery reveals increased burden of pathogenic TP53 mutations in BRCA1 carriers. This excess of pathogenic TP53 mutations might be linked to the elevated risk of HGSC in these individuals. In some patients, concordant TP53 mutations were found in peritoneal washes and cervical LBCs, but the cell of origin remains unknown and deserves further investigation.

Indexed as

BRCA1 ProteinGerm-Line MutationOvarian NeoplasmsTumor Suppressor Protein p53AdultAgedCystadenocarcinoma, SerousFemaleGenes, BRCA1High-Throughput Nucleotide SequencingHumansMiddle AgedBRCA1 ProteinBRCA1 protein, humanTP53 protein, humanTumor Suppressor Protein p53BRCA mutationsClonal expansionsOvarian cancer riskPap testsPathogenic mutationsTP53 mutations

Identifiers

PMID39128337
PMCPMC11560739

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.